XTL Biopharmaceuticals Acquires NeuroNOS, Entering Autism Market with Nobel Laureates

XTL Biopharmaceuticals has acquired 85% of Beyond Air's subsidiary NeuroNOS, entering the autism market with Nobel Prize-winning scientific leadership. Two Nobel Laureates join Founder Prof. Haitham Amal, a global autism researcher. The platform targets the core biology of autism, not just symptomatic relief. Beyond Air will hold 19.99% of XTL's post-transaction share capital and receive up to $32.5 million in upfront, development, and commercial milestone payments.